?
Læs mere om arbejdspladslogin her.

Content area

Videnskab / 5. feb 2018

Nye antidiabetiske lægemidler og kardiovaskulære komplikationer

Statusartikel
Dato
5. feb 2018
Forfattere
Manan Pareek1, 2, 3, Martin Bødtker Mortensen4, 5, Bo Løfgren4, Mette Lundgren Nielsen3, Michael Hecht Olsen2 & Niels Holmark Andersen6 1) Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, Boston, USA 2) Medicinsk Afdeling, Holbæk Sygehus 3) Endokrinologisk Afdeling, Odense Universitetshospital 4) Medicinsk Afdeling, Regionshospitalet Randers 5) Afdeling for Hjertesygdomme, Aarhus Universitetshospital 6) Kardiologisk Afdeling, Aalborg Universitetshospital Ugeskr Læger 2018;180:V07170551
💬 0
Reference: 
Ugeskr Læger 2018;180:V07170551
Sidetal: 
2-6
Novel antidiabetic drugs and cardiovascular complications
This review summarizes the cardiovascular non-inferiority trials of novel antidiabetic drugs performed since 2008, when regulatory agencies started mandating thorough examination of their cardiovascular safety. So far, eight randomized trials on three different drug classes have been completed. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce cardiovascular risk and possibly mortality, while dipeptidyl dipeptidase-4 inhibitors may increase the risk of heart failure. A brief discussion of potential mechanisms and clinical implications is provided.

💬 0 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Du kan også købe adgang

Køb abonnement til Ugeskriftet.dk (der er forskellige abonnementstyper )

Right side

Nr. 4/2018

Senest kommenteret

Lægeforeningen: Det risikobaserede tilsyn fungerer ikke
💬
1
Lars Erik Larsen 20. feb 2018 15:25
Luftguitar, kvakademisk forskning og Cochrane
💬
11
Karsten Juhl Jørgensen 20. feb 2018 12:01
Billeddiagnostisk udredning ved mistanke om akut lungeemboli
💬
1
Jens Aamann Andersen 19. feb 2018 17:27